RLAY (Relay Therapeutics) Earnings growth in current year

Official company branding of relaytx.com (RLAY)

Annual EPS fluctuations demonstrate the earnings per share trend, where the value of 3.40 serves as the current metric. Relay Therapeutics (RLAY) is recognized as a visionary in digital drug design, enjoying the absolute trust of the scientific community. Market capitalization is based on payments from pharma behemoths for AI solutions, while the development strategy relies on deep R&D partnerships without mergers.

RLAY (Relay Therapeutics, Inc.) Earnings growth in current year history from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for Relay Therapeutics (RLAY)

- share price and expert price forecast:
Price Relay Therapeutics Inc|RLAY - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Relay Corp|RLAY - Total Company Value
- book capitalization data:
Accounting Value of a Share Relay Therapeutics|RLAY - Book Capitalization|Market Value to Equity Ratio relaytx.com|RLAY - Company Total Assets
- debt and liquidity details:
Debt to Capital Relay Therapeutics|RLAY - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio relaytx.com|RLAY - Company Aggregate Debts|Debts to Book Value Relay Corp|RLAY - Company Long-Term Debts|Company Short-Term Indebtedness Relay Therapeutics|Intermediate Coverage Ratio relaytx.com
- net income and valuation multiples indicators:
RLAY - Net Income|Future Net Profit Relay Therapeutics|RLAY - P/E Multiple|Future Price to Earnings Multiple Relay Corp|RLAY - PEG Multiple|Company Value to EBITDA Relay Corp|RLAY - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Relay Therapeutics|RLAY - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth relaytx.com|RLAY - Earnings per share growth in current year|Net earnings per share change forecast for next year Relay Therapeutics
Fundamental valuation:RLAY Relay Therapeutics Inc
Signature product of Relay Corp

The innovative model of Relay Therapeutics (RLAY), which utilizes an AI platform for protein analysis, determines the current annual EPS variability. This indicator captures the percentage deviation of earnings per share relative to the previous period, allowing for an assessment of financial stability and the efficiency of capitalizing patents for oncology molecules under strict FDA regulatory control.

Direct competitors

GMAB: Net earnings per one share growth for the current year|EXEL (Exelixis Corp) - Earnings growth in current year|Earnings growth in current year Nuvalent Therapeutics|Earnings per share growth in current year Kymera Therapeutics (KYMR)|IDYA (ideayabio.com) - Earnings per share increase in current year|Earnings growth in current year ELVN (Enliven Therapeutics, Inc.)|Net earnings per share change in current year ORIC Pharmaceuticals Inc|Nurix Pharma - Earnings growth in current year|Earnings per share growth rate in current year Tyra Corp|VSTM (Verastem, Inc.) - Net earnings per share growth this year|GLUE: Net earnings per one share growth for the current year|CGEM (Cullinan Therapeutics, Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Immuneering Corp IMRX|Earnings growth in current year CCCC|Black Diamond Therapeutics, Inc - Earnings per share growth this year|Repare Therapeutics - Net earnings per share growth this year|Earnings per share increase in current year PMVP|KPTI: Net earnings per share growth this year|Propanc Biopharma Inc - Net earnings per one share growth for the current year|BGMS: Earnings growth in current year|Aadi Bioscience, Inc. - Earnings per share increase in current year|ALRN (Aileron Therapeutics Inc) - Earnings growth in current year|Earnings per share growth rate in current year Blueprint Medicines Corp BPMC|Earnings per share growth in current year GlycoMimetics, Inc. (GLYC)|SWTX (SpringWorks Therapeutics Inc.) - Earnings per share increase in current year